» Articles » PMID: 35963908

Loss of FGFR4 Promotes the Malignant Phenotype of PDAC

Abstract

Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to clarify the role of FGFR1 and FGFR4 in the definition of aggressive PDAC phenotypes. We found that the expression of FGFR4 is exclusively detected in epithelial cells, significantly elevated in the classical PDAC subtype, and associates with better outcomes. In highly aggressive basal-like/squamous PDAC, reduced FGFR4 expression aligns with hypermethylation of the gene and lower levels of histone marks associated with active transcription in its regulatory regions. Conversely, FGFR1 has more promiscuous expression in both normal and malignant pancreatic tissues and is strongly associated with the EMT phenotype but not with the basal-like cell lineage. Regardless of the genetic background, the increased proliferation of FGFR4-depleted PDAC cells correlates with hyperactivation of the mTORC1 pathway both in vitro and in vivo. Downregulation of FGFR4 in classical cell lines invariably leads to the enrichment of basal-like/squamous gene programs and is associated with either partial or full switch of phenotype. In sum, we show that endogenous levels of FGFR4 limit the malignant phenotype of PDAC cells. Finally, we propose FGFR4 as a valuable marker for the stratification of PDAC patients.

Citing Articles

Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer.

Veghini L, Pasini D, Fang R, Delfino P, Filippini D, Neander C Nat Commun. 2024; 15(1):10534.

PMID: 39627211 PMC: 11615044. DOI: 10.1038/s41467-024-54975-8.


Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression-A Scoping Review.

Orlandi E, Guasconi M, Vecchia S, Trubini S, Giuffrida M, Proietto M Cancers (Basel). 2024; 16(16).

PMID: 39199681 PMC: 11352631. DOI: 10.3390/cancers16162912.


FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium.

Easter M, Hirsch M, Harris E, Howze 4th P, Matthews E, Jones L JCI Insight. 2024; 9(15).

PMID: 38916962 PMC: 11383597. DOI: 10.1172/jci.insight.174888.


Association of the rs1966265 and rs351855 Variants with Colorectal Cancer in a Mexican Population and Their Analysis In Silico.

Carrillo-Davila I, Garibaldi-Rios A, Figuera L, Gomez-Meda B, Zuniga-Gonzalez G, Puebla-Perez A Biomedicines. 2024; 12(3).

PMID: 38540215 PMC: 10968131. DOI: 10.3390/biomedicines12030602.


TRPA1 Contributes to FGFR2c Signaling and to Its Oncogenic Outcomes in Pancreatic Ductal Adenocarcinoma-Derived Cell Lines.

Mancini V, Raffa S, Fiorio Pla A, French D, Torrisi M, Ranieri D Cancers (Basel). 2024; 16(3).

PMID: 38339360 PMC: 10854535. DOI: 10.3390/cancers16030609.

References
1.
Rahib L, Wehner M, Matrisian L, Nead K . Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021; 4(4):e214708. PMC: 8027914. DOI: 10.1001/jamanetworkopen.2021.4708. View

2.
Bailey P, Chang D, Nones K, Johns A, Patch A, Gingras M . Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52. DOI: 10.1038/nature16965. View

3.
Chan-Seng-Yue M, Kim J, Wilson G, Ng K, Figueroa E, OKane G . Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020; 52(2):231-240. DOI: 10.1038/s41588-019-0566-9. View

4.
Collisson E, Bailey P, Chang D, Biankin A . Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(4):207-220. DOI: 10.1038/s41575-019-0109-y. View

5.
Moffitt R, Marayati R, Flate E, Volmar K, Loeza S, Hoadley K . Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015; 47(10):1168-78. PMC: 4912058. DOI: 10.1038/ng.3398. View